Key result
R-CHOP-like regimens linked to ~8-point greater rise in cardiac extracellular volume vs R-B.
Why the study?
To evaluate changes in epicardial adipose tissue and cardiac extracellular volume in patients with follicular lymphoma treated with R-CHOP-like regimens versus R-bendamustine.
Does anthracycline-based R-CHOP-like therapy cause greater detrimental changes in surrogate imaging markers of cardiac toxicity compared to R-bendamustine in patients with follicular lymphoma?
Cohort (n=80)
No
Does anthracycline-based R-CHOP-like therapy cause greater detrimental changes in surrogate imaging markers of cardiac toxicity compared to R-bendamustine in patients with follicular lymphoma?
In older patients with follicular lymphoma, anthracycline-based R-CHOP-like regimens induce significantly greater subclinical cardiotoxic changes on CT (increased ECV and decreased EAT density) and echocardiography compared to anthracycline-free R-bendamustine therapy.
Answers are grounded in this paper and cite their sources.
May signal higher subclinical cardiotoxicity risk with anthracyclines in older FL patients; leaves open whether ECV changes predict clinical events.
The aim of this study is to evaluate changes in epicardial adipose tissue (EAT) and cardiac extracellular volume (ECV) in patients with follicular lymphoma (FL) treated with R-CHOP-like regimens or R-bendamustine. We included 80 patients with FL between the ages of 60 and 80 and, using computed tomography (CT) performed at onset and at the end of treatment, we assessed changes in EAT by measuring tissue density at the level of the cardiac apex, anterior interventricular sulcus and posterior interventricular sulcus of the heart. EAT is known to be associated with metabolic syndrome, increased calcium in the coronary arteries and therefore increased risk of coronary artery disease. We also evaluated changes in ECV, which can be used as an early imaging marker of cardiac fibrosis and thus myocardial damage. The R-CHOP-like regimen was associated with lower EAT values (p < 0.001), indicative of a less active metabolism and more adipose tissue, and an increase in ECV (p < 0.001). Furthermore, in patients treated with anthracyclines and steroids (R-CHOP-like) there is a greater decrease in ejection fraction (EF p < 0.001) than in the R-B group. EAT and ECV may represent early biomarkers of cardiological damage, and this may be considered, to our knowledge, the first study investigating radiological and cardiological parameters in patients with FL.
No takes yet. Share an insight, caveat, or question.
Esposito et al. (2024) conducted a cohort in Follicular Lymphoma (n=80). R-CHOP-like regimens (anthracycline-based) vs. R-bendamustine (R-B) was evaluated on Change in cardiac extracellular volume (Δ ECV) (p=<0.001). R-CHOP-like treatment in follicular lymphoma patients was associated with a greater increase in cardiac extracellular volume compared to R-B, indicating early cardiac damage.
Synapse has enriched 10 related papers. Consider them for comparative context: